Prognostic significance of PD-L1 and PD-L2 in breast cancer

Baptista, Mauricio Z.; Sarian, Luís Otávio; Derchain, Sophie; Pinto, Glauce Aparecida; Vassallo, José

doi:10.1016/j.humpath.2015.09.006

Cited by 224 publications

(217 citation statements)

References 26 publications

Supporting

Mentioning

196

Contrasting

Unclassified

Order By: Relevance

“…(25), found that high PD-L1 protein expression was associated with shorter survival which was like our reults.PD-L1 expression in malignant cells is a recent prognostic marker that could prove the antitumor immunity interruption .Previous studies proved that PD-L1 overexpression was an important prognostic factor in malignancies of many organs (26) . PD-L1 overexpression and relations to patient prognosis differ according to cancer type (27).…”

Section: Hamanishi Et Al 2007(16)supporting

confidence: 88%

Prognostic and Predictive Significance of Programmed Death Ligand (Pd-L1) and Foxp3 Expressions in Tumor Cells and Tumor Microenvironment in Ovarian Cancer Patients.

Abdelaziz.¹,

Shorbagy.²,

Elfarargy³

et al. 2017

IJAR

View full text Add to dashboard Cite

Background:The microenvironment of epithelial ovarian cancer (EOC) continued to be an important point of research to discover new therapeutic targets for such malignancy. It was discovered that any cells that were in the microenvironment of the EOC may be associated with cancer prognosis like tumor-infiltrating lymphocytes (TILs) and Tregulatory cells (Tregs). The PD-1/PD-L1 pathway was a T-cell checkpoint pathway that sent inhibitory signals to T cells that can inhibit immunity. PDL1, a PD-1 ligand, is detected in lymphocytes, dendritic cells, macrophages and tumor cells. Tregs (mature T lymphocytes) that start in the thymus after stimulation of naïve T cells and responsible for the reduction of autoimmune diseases, but its over production will inhibit endogenous protection against infection and tumors. Forkhead/winged-helix transcription factor box P3 (Foxp3) is an intracellular molecule for Tregs growth and maturation and was found to be the most specific Tregs marker. It was found that Foxp3 is not only found in Treg cells that originated in the thymus but also in malignant cells and its difference in expression can affect the outcome of cancer patients. Aim of our study: was to assess PD-L1 and FOXP3 expression in epithelial ovarian carcinoma a trial to detect their prognostic value and their impact on survival in patients with such type of cancer. Methods: The expressions of PD-L1 and FOXP3 in both tumor cells and stromawere evaluated in sections of 50 paraffin blocks that were retrieved from 50 patients with EOC using immunohistochemistry.We assessed the relation between their expressions, clinicopathological parameters, survival and prognosis of those patients

show abstract

Section: Hamanishi Et Al 2007(16)supporting

confidence: 88%

Prognostic and Predictive Significance of Programmed Death Ligand (Pd-L1) and Foxp3 Expressions in Tumor Cells and Tumor Microenvironment in Ovarian Cancer Patients.

Abdelaziz.¹,

Shorbagy.²,

Elfarargy³

et al. 2017

IJAR

View full text Add to dashboard Cite

show abstract

“…PD-L1 expression was associated with triple-negative tumors, higher grade and size, node positivity and a worse prognosis. Still, another immunohistochemistry study examining both PD-L1 and PD-L2 in 192 stage I to III breast cancer patients showed 56.6% and 50.8% to be positive, respectively, and confirmed that positive tumors were more often ER-negative and lymph node-positive (26). Unexpectedly, despite a higher distant recurrence rate in PD-L1 positive patients, their overall survival was better than PD-L1-negative patients, a fact that the authors attributed to a stronger underlying anti-tumor immune response leading to the observed PD-L1 positivity (26).…”

Section: Ctla-4mentioning

confidence: 85%

Immune Blockade Inhibition in Breast Cancer

Voutsadakis

2016

View full text Add to dashboard Cite

“…PD-1 interacts with two known ligands: PD-L1 and PD-L2 (Latchman et al 2001). PD-L1 expression was initially reported on melanoma, ovarian, colon and lung cancer cells (Dong et al 2002) but can also be found in other human cancers such as breast (Baptista et al 2016), head and neck (Malm et al 2015) and pancreatic cancer (Bigelow et al 2013). Interaction of PD-1 with PD-L1 has been conceived to act as an immune evasion mechanism for tumor cells (Dong et al 2002, Iwai et al 2002, Wu et al 2006.…”

Section: Immune Checkpoint Inhibitors: the Milestone In Immunooncologymentioning

confidence: 99%

“…PD-L2 is upregulated in follicular B-cell lymphoma, Hodgkin lymphoma and primary mediastinal B-cell lymphoma (Rosenwald et al 2003). Recent research could also identify an overexpression of PD-L2 in more than 50% of breast cancer samples (Baptista et al 2016) and esophageal squamous cell carcinoma but no correlation was found with disease-free survival and/or overall survival (Leng et al 2016). So far, no therapeutics directly target PD-L2.…”

Section: :10mentioning

confidence: 99%

Perspectives for immunotherapy in endocrine cancer

Latteyer¹,

Tiedje²,

Schilling³

et al. 2016

Endocrine-Related Cancer

View full text Add to dashboard Cite

The fight against cancer has seen major breakthroughs in recent years. More than a decade ago, tyrosine kinase inhibitors targeting constitutively activated signaling cascades within the tumor inaugurated a new era of oncological therapy. Recently, immunotherapy with immune checkpoint inhibitors has started to revolutionize the treatment of several malignancies, most notably malignant melanoma, leading to the renaissance and the long-awaited breakthrough of immunooncology. This review provides an overview of the basis of immunotherapy from its initial concepts of antitumor immunity and cell-based therapy to the development of immune checkpoint inhibitors and discusses published studies and the perspectives of immunooncology for the treatment of endocrine malignancies.

show abstract

Prognostic significance of PD-L1 and PD-L2 in breast cancer

Cited by 224 publications

References 26 publications

Prognostic and Predictive Significance of Programmed Death Ligand (Pd-L1) and Foxp3 Expressions in Tumor Cells and Tumor Microenvironment in Ovarian Cancer Patients.

Prognostic and Predictive Significance of Programmed Death Ligand (Pd-L1) and Foxp3 Expressions in Tumor Cells and Tumor Microenvironment in Ovarian Cancer Patients.

Immune Blockade Inhibition in Breast Cancer

Perspectives for immunotherapy in endocrine cancer

Contact Info

Product

Resources

About